Internal Medicine, Hematology & Oncology · San Francisco, CA
NPI
1518155357
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2100 Webster St Ste 225
San Francisco, CA, 94115
Phone (415) 923-3012
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
103,008 services
Medicare patients, 2024
586
Average age 77
Drug cost, 2024
$8.3M
1,659 prescriptions
Company payments, 2025
$1,450
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Caroline M Behler was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 19,380 times for 20 patients. In total Caroline M Behler billed 103,008 services in 116 codes, and Medicare paid $1.9M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-28.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 19,380 | 20 | $0.27 | $5,237 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 18,510 | 27 | $2.32 | $43K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 8,132 | 11 | $38.83 | $316K |
| J0897 Injection, denosumab, 1 mg | Office | 6,321 | 26 | $20.66 | $131K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 5,607 | 14 | $44.37 | $249K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,407 | 48 | $0.09 | $128 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,165 | 44 | $0.74 | $867 |
| 99214 Office E&M - Established | Office | 917 | 406 | $112.55 | $103K |
| 85025 Blood Count | Office | 711 | 194 | $7.58 | $5,388 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 387 | 12 | $3.71 | $1,434 |
| 96413 Chemotherapy Administration | Office | 268 | 76 | $137.63 | $37K |
| J9190 Injection, fluorouracil, 500 mg | Office | 267 | 12 | $2.29 | $611 |
| 96372 Injection Administration | Office | 267 | 82 | $14.06 | $3,753 |
| 99215 Office E&M - Established | Office | 197 | 117 | $166.35 | $33K |
| 96401 Chemotherapy Administration | Office | 154 | 21 | $74.36 | $11K |
By year: 2022 $1.7M for 92,803 services; 2023 $2.0M for 124,328 services; 2024 $1.9M for 103,008 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 711 | 194 | $7.58 | $5,388 |
Medicare prescription drug claims, 2024
In 2024, the drug Caroline M Behler prescribed most often to Medicare patients was Hydroxyurea, with 109 prescriptions and refills. In total Caroline M Behler wrote 1,659 Medicare prescriptions that cost $8.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 109 | 259 | 24 | $2,154 |
| Revlimid Lenalidomide | 79 | 79 | 12 | $1.1M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 75 | 85 | 11 | $311 |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 62 | 62 | Under 11 | $587K |
| Xgeva Denosumab | 58 | 58 | Under 11 | $185K |
| Anastrozole Generic | 57 | 157 | 20 | $2,015 |
| Venclexta Venetoclax | 54 | 54 | Under 11 | $258K |
| Acyclovir Generic | 47 | 59 | Under 11 | $573 |
| Aranesp Darbepoetin Alfa In Polysorbat | 47 | 47 | Under 11 | $103K |
| Letrozole Generic | 44 | 108 | Under 11 | $1,864 |
| Eliquis Apixaban | 43 | 61 | Under 11 | $35K |
| Dexamethasone Generic | 38 | 42 | Under 11 | $743 |
| Lenalidomide Generic | 36 | 36 | Under 11 | $436K |
| Xarelto Rivaroxaban | 34 | 52 | Under 11 | $31K |
| Jakafi Ruxolitinib Phosphate | 33 | 39 | Under 11 | $451K |
Brand drugs: 842 claims; generic drugs: 817 claims; opioid claims: 39.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Caroline M Behler $1,450 ($1,450 in general payments such as food, travel and fees) from 31 companies. The largest payer was Celgene Corporation with $173.
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation BMY | 8 | $173 |
| Pfizer Inc. PFE | 6 | $155 |
| Abbvie Inc. ABBV | 3 | $74.92 |
| Taiho Oncology, Inc. 4578.T | 2 | $71.22 |
| Exelixis Inc. EXEL | 2 | $68.26 |
| Janssen Biotech, Inc. JNJ | 2 | $64.95 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $62.99 |
| Genentech USA, Inc. ROG.SW | 2 | $60.09 |
| GlaxoSmithKline, LLC. GSK | 2 | $51.78 |
| Adc Therapeutics America, Inc. | 2 | $50.21 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.